This study is not yet accepting patients

The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19

a study on COVID-19

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Irvine
Dates
study started
completion around
Principal Investigator
by Alpesh N Amin (uci)

Description

Summary

The purpose of this research study is to assess if glutathione, along with NAC (N-acetyl cysteine) and Alpha lipoic acid (ALA), can help reverse some of the COVID long-haul symptoms.Subjects will be randomized in to one of two groups. Depending on the group they are randomized in to, subjects will be taking either a combination of NAC, Alamax CR, and liposomal GSH or the same three nutritional supplements with a multivitamin and magnesium. Regardless of the group, subjects will be asked questions to assess their COVID symptoms, physical and mental health status. They will also be asked to take blood samples.

Keywords

COVID-19, Covid-19 Long-Haul, Post-Acute COVID-19 Syndrome, Thioctic Acid, Acetylcysteine, N-monoacetylcystine, NAC (N-acetyl cysteine) , Alpha lipoic acid (ALA), liposomal glutathione (GSH)

Eligibility

You can join if…

Open to people ages 18 years and up

• Patients with positive COVID testing (AB, RT PCR) and mild-severe symptoms based on COVID symptom list

You CAN'T join if...

• History of a severe sulfa sensitivity (i.e., anaphylaxis, Stevens Johnson Syndrome), allergy to meat products and/or gelatin (alpha gal allergy) and/or a history of an allergic or adverse reaction to NAC, alpha lipoic acid and/or GSH.

Location

  • University of California Irvine Medical Center
    Orange California 92868 United States

Lead Scientist at University of California Health

  • Alpesh N Amin (uci)
    Clinical Professor, Medicine, School of Medicine. Authored (or co-authored) 269 research publications

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Irvine
ID
NCT05371288
Phase
Phase 1 COVID-19 Research Study
Study Type
Interventional
Participants
Expecting 50 study participants
Last Updated